These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18291644)

  • 1. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
    Salvati ME; Balog A; Shan W; Rampulla R; Giese S; Mitt T; Furch JA; Vite GD; Attar RM; Jure-Kunkel M; Geng J; Rizzo CA; Gottardis MM; Krystek SR; Gougoutas J; Galella MA; Obermeier M; Fura A; Chandrasena G
    Bioorg Med Chem Lett; 2008 Mar; 18(6):1910-5. PubMed ID: 18291644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and biological characterization of a novel series of androgen receptor modulators.
    Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
    Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
    Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
    Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.
    Salvati ME; Balog A; Wei DD; Pickering D; Attar RM; Geng J; Rizzo CA; Hunt JT; Gottardis MM; Weinmann R; Martinez R
    Bioorg Med Chem Lett; 2005 Jan; 15(2):389-93. PubMed ID: 15603960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circumventing anti-androgen resistance by molecular design.
    McGinley PL; Koh JT
    J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.
    Guo C; Linton A; Kephart S; Ornelas M; Pairish M; Gonzalez J; Greasley S; Nagata A; Burke BJ; Edwards M; Hosea N; Kang P; Hu W; Engebretsen J; Briere D; Shi M; Gukasyan H; Richardson P; Dack K; Underwood T; Johnson P; Morell A; Felstead R; Kuruma H; Matsimoto H; Zoubeidi A; Gleave M; Los G; Fanjul AN
    J Med Chem; 2011 Nov; 54(21):7693-704. PubMed ID: 21936524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of a potent orally efficacious indole androgen receptor antagonist through in vivo screening.
    Lanter JC; Fiordeliso JJ; Jiang W; Allan GF; Lai MT; Linton O; Hahn do W; Lundeen SG; Sui Z
    Bioorg Med Chem Lett; 2007 Jan; 17(1):123-6. PubMed ID: 17071085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Landriscina M; Bagalà C; Piscazzi A; Schinzari G; Quirino M; Fabiano A; Bianchetti S; Cassano A; Sica G; Barone C
    Prostate; 2009 May; 69(7):744-54. PubMed ID: 19152342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.
    Salvati ME; Balog A; Shan W; Wei DD; Pickering D; Attar RM; Geng J; Rizzo CA; Gottardis MM; Weinmann R; Krystek SR; Sack J; An Y; Kish K
    Bioorg Med Chem Lett; 2005 Jan; 15(2):271-6. PubMed ID: 15603938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on "Androgen-hypersensitive preclinical model of prostate cancer" by Kawata et al.
    Foley R; Marignol L; Keane JP; Lynch TH; Hollywood D
    Prostate; 2011 May; 71(6):559-60. PubMed ID: 20945499
    [No Abstract]   [Full Text] [Related]  

  • 12. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.
    Attar RM; Jure-Kunkel M; Balog A; Cvijic ME; Dell-John J; Rizzo CA; Schweizer L; Spires TE; Platero JS; Obermeier M; Shan W; Salvati ME; Foster WR; Dinchuk J; Chen SJ; Vite G; Kramer R; Gottardis MM
    Cancer Res; 2009 Aug; 69(16):6522-30. PubMed ID: 19654297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer: Could an antimalarial drug delay the onset of CRPC?
    Clyne M
    Nat Rev Urol; 2013 Jun; 10(6):307. PubMed ID: 23588402
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.
    van Oeveren A; Pio BA; Tegley CM; Higuchi RI; Wu M; Jones TK; Marschke KB; Negro-Vilar A; Zhi L
    Bioorg Med Chem Lett; 2007 Mar; 17(6):1523-6. PubMed ID: 17257838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors.
    Gravina GL; Marampon F; Di Staso M; Bonfili P; Vitturini A; Jannini EA; Pestell RG; Tombolini V; Festuccia C
    Prostate; 2010 Aug; 70(11):1166-78. PubMed ID: 20333699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
    Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
    Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of FGF8 expression by the androgen receptor in human prostate cancer.
    Gnanapragasam VJ; Robson CN; Neal DE; Leung HY
    Oncogene; 2002 Aug; 21(33):5069-80. PubMed ID: 12140757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
    Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
    Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgen receptor antagonists.
    Ng RA; Guan J; Alford VC; Lanter JC; Allan GF; Sbriscia T; Lundeen SG; Sui Z
    Bioorg Med Chem Lett; 2007 Feb; 17(4):955-8. PubMed ID: 17134895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.